Search our Database of Scientific Publications and Authors

I’m looking for a

    91 results match your criteria Utility of Bone Markers in Osteoporosis

    1 OF 2

    Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rat.
    Am J Transl Res 2017 15;9(7):3517-3527. Epub 2017 Jul 15.
    Nordic Bioscience (Beijing) Ltd.Beijing, China.
    The clinical utility of Traditional Chinese Medicine (TCM) herbs/roots extracts in osteoporosis (OP) and osteoarthritis (OA) has been described in multiple reports, but there have been few studies of TCM for preventing bone loss and cartilage degradation simultaneously. Six-month-old female Sprague-Dawley rats each were subjected to ovariectomized (OVX) or sham surgery and treated orally once daily with herbal extracts or vehicle. Body weight was recorded weekly, and blood samples were collected from fasting animals at different time points. Read More

    Urinary Bone Turnover Markers as Target Indicators for Monitoring Bisphosphonate Drug Treatment in the Management of Osteoporosis.
    Curr Drug Targets 2017 Jul 4. Epub 2017 Jul 4.
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 2-020J Katz Group Centre for Pharmacy & Health Research, 11361 - 87 Ave., Edmonton, Alberta, T6G 2E1. Canada.
    Osteoporosis is a debilitating disease characterized by bone micro-architecture degradation contributing to fragility fractures. Currently, determining bone mineral density (BMD) via dual-energy X-ray absorptiometry (DXA) is the most reliable form of diagnosing osteoporosis and managing pharmacological treatment regimens. However, changes in BMD occur slowly (i. Read More

    Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
    Endocr Rev 2017 Jun 23. Epub 2017 Jun 23.
    Division of Endocrinology and Kogod Center on Aging, Mayo Clinic College of Medicine, Rochester, Minnesota 55905 USA.
    Cathepsin K is a cysteine protease member of the cathepsin lysosomal protease family. While cathepsin K is highly expressed in osteoclasts, lower levels of cathepsin K are also found in a variety of other tissues. Secretion of cathepsin K from the osteoclast into the sealed osteoclast-bone cell interface results in efficient degradation of type I collagen. Read More

    Measurement and Clinical Utility of βCTX in Serum and Plasma.
    Adv Clin Chem 2017 16;81:97-134. Epub 2017 Feb 16.
    PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, WA, Australia. Electronic address:
    Biochemical markers of bone turnover (BTM) are released during bone remodeling and can be measured in blood or urine as noninvasive surrogate markers for the bone remodeling rate. The C-terminal cross-linked telopeptide of type I collagen (βCTX) is released during bone resorption and is specific to bone tissue. Assays have been developed to measure βCTX in blood and in urine; most current use of βCTX measurement for research and in clinical practice is performed on a blood sample. Read More

    The Utility of Biomarkers in Osteoporosis Management.
    Mol Diagn Ther 2017 Aug;21(4):401-418
    Department of Internal Medicine Specialties, Division of Bone Diseases, University Hospital of Geneva, 64 Av de la Roseraie, CH-1205, Geneva, Switzerland.
    The measurement of bone turnover markers is useful for the clinical investigation of patients with osteoporosis. Among the available biochemical markers, the measurements of serum procollagen type I N-terminal propeptide (PINP) and the crosslinked C-terminal telopeptide (serum CTX) have been recommended as reference markers of bone formation and bone resorption, respectively. The important sources of preanalytical and analytical variability have been identified for both markers, and precise measurement can now be obtained. Read More

    Elevated Bone Turnover Markers Are Associated With Distal Radius Fractures in Premenopausal Women.
    J Hand Surg Am 2017 Feb;42(2):71-77
    Department of Orthopaedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address:
    Purpose: To examine whether premenopausal women with distal radius fractures (DRF) have lower levels of 25-hydroxyvitamin D (25[OH]D) and increased levels of serum bone turnover markers (BTM) compared with control subjects without fracture.

    Methods: Premenopausal women with DRF (n = 20) were prospectively enrolled and compared with age-matched individuals without a fracture (n = 20). Outcome measures included serum levels of 25(OH)D, parathyroid hormone (PTH), markers of bone formation (osteocalcin [OC], N-terminal extension propeptide of type I collagen [P1NP], and bone-specific alkaline phosphatase [BSAP]), and markers of bone resorption (C-terminal telopeptide of type I collagen [CTX]). Read More

    Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.
    Clin Chem 2017 Feb 9;63(2):464-474. Epub 2016 Dec 9.
    Endocrine Unit, Massachusetts General Hospital, Boston, MA.
    Background: Disorders of bone metabolism, most notably osteoporosis, are highly prevalent and predispose to fractures, causing high patient morbidity and mortality. Diagnosis and monitoring of bone metabolic defects can present a major challenge as these disorders are largely asymptomatic and radiographic measures of bone mass respond slowly to changes in bone physiology.

    Content: Bone turnover markers (BTMs) are a series of protein or protein derivative biomarkers released during bone remodeling by osteoblasts or osteoclasts. Read More

    Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.
    Mol Ther Nucleic Acids 2016 Sep 13;5(9):e363. Epub 2016 Sep 13.
    NanoMedicines Research Group, Department of Biochemistry and Molecular Biology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.
    Sclerostin is a protein secreted by osteocytes that is encoded by the SOST gene; it decreases bone formation by reducing osteoblast differentiation through inhibition of the Wnt signaling pathway. Silencing the SOST gene using RNA interference (RNAi) could therefore be an effective way to treat osteoporosis. Here, we investigate the utility of lipid nanoparticle (LNP) formulations of siRNA to silence the SOST gene in vitro and in vivo. Read More

    The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis.
    Endocrine 2016 May 23;52(2):222-5. Epub 2016 Feb 23.
    Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, 102-118 Murdoch Drive, Murdoch, WA, 6150, Australia.
    The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. Read More

    A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
    J Bone Miner Res 2016 Apr 24;31(4):874-81. Epub 2016 Jan 24.
    Department of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.
    Mutations in the LRP4 gene, coding for a Wnt signaling coreceptor, have been found to cause several allelic conditions. Among these, two are characterized by a strong skeletal involvement, namely sclerosteosis and Cenani-Lenz syndrome. In this work, we evaluated the role of LRP4 in the pathophysiology of these diseases. Read More

    [Bone and Calcium Research Update 2015. Therapy of osteoporosis--Now and future consideration of long-term therapy].
    Clin Calcium 2015 Jan;25(1):105-13
    Department of Obstetrics and Gynecology, Hori Hospital, Japan.
    The target to treat osteoporosis is prevention for future fractures. After the evaluation of cathepsin K inhibitors (CKIs) which was developed as antresorptive agents, there is evidence that these agents also possess anabolic activity, suggesting that CKIs differ from so called antiresorptive agents such as bisphosphonates and denosumab. The classification of agents for treatment of osteoporosis has been changed. Read More

    Reference intervals for bone turnover markers and their association with incident hip fractures in older men: the Health in Men study.
    J Clin Endocrinol Metab 2015 Jan;100(1):90-9
    School of Pathology and Laboratory Medicine (S.A.P.C., J.P.B., S.D.V.) and School of Medicine and Pharmacology (S.A.P.C., L.M., L.F., B.B.Y.), University of Western Australia, Crawley, Western Australia 6009, Australia; Biochemistry Department (S.A.P.C., E.B., J.P.B., S.D.V.), PathWest Laboratory Medicine, Nedlands, 6009 Western Australia, Australia; Department of Medicine (P.R.E.), Monash University, Clayton, Victoria 3146, Australia; Queensland Research Centre for Peripheral Vascular Disease (J.G.), School of Medicine and Dentistry, James Cook University, Townsville 4811, Queensland; Department of Vascular and Endovascular Surgery (J.G.), The Townsville Hospital, Townsville, Queensland 4810, Australia; and Department of Endocrinology and Diabetes (B.B.Y.), Fremantle Hospital, Fremantle 6160, Western Australia, Australia.
    Context: Reference intervals for bone turnover markers (BTMs) and relationships between BTM and fracture risk in older men are not well characterized.

    Objective: The purpose of this article was to determine the reference intervals for serum total osteocalcin (tOC), undercarboxylated osteocalcin (ucOC), N-terminal propeptide of type I collagen (PINP), and collagen type I C-terminal cross-linked telopeptide (CTX-I) in healthy older men and to explore factors associated with BTMs, including hip fracture risk.

    Participants And Setting: We studied a population-based cohort of 4248 men aged 70 to 89 years, 4008 of whom had serum samples available for analysis. Read More

    Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS).
    Osteoporos Int 2015 Feb 16;26(2):617-27. Epub 2014 Sep 16.
    Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium,
    Summary: The aim of this study was to determine whether bone turnover markers (BTMs) predict changes in areal bone mineral density (aBMD) in middle-aged and elderly European men. Older men with high bone turnover are at a higher risk of accelerated hip bone loss, but the clinical utility of BTMs in individuals is limited.

    Introduction: Prospective studies on the value of BTMs to predict changes in aBMD in men are few and conflicting. Read More

    Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Maturitas 2014 Jul 2;78(3):199-204. Epub 2014 May 2.
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, United States. Electronic address:
    Monoclonal antibodies to molecular targets important for bone formation and bone resorption are being investigated for treatment of postmenopausal osteoporosis. Postmenopausal osteoporosis is characterized by increased bone turnover, with bone resorption typically exceeding bone formation. These pathophysiological changes cause decreased bone mineral density and disruption of bone microarchitecture which lead to low-trauma fractures. Read More

    Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
    Health Technol Assess 2014 Feb;18(11):1-180
    Centre for Reviews and Dissemination, York, UK.
    Background: There is currently no standard practice for the monitoring of patients receiving treatment for osteoporosis. Repeated dual-energy X-ray absorptiometry (DXA) is commonly used for monitoring treatment response, but it has its limitations. Bone turnover markers have advantages over DXA as they are non-invasive, relatively cheap and can detect changes in bone turnover rates earlier. Read More

    The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B.
    Haemophilia 2014 Mar 7;20(2):268-75. Epub 2013 Oct 7.
    Haemophilia Centre of Northern Greece, Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
    Haemophilia A and B have been associated with increased prevalence of low bone mineral density (BMD). However, the utility of bone turnover markers (BTM) remains unknown. The aim of this study was to evaluate bone metabolism in men with haemophilia and to investigate associations between BTM and bone disease. Read More

    The clinical utility of bone marker measurements in osteoporosis.
    J Transl Med 2013 Aug 29;11:201. Epub 2013 Aug 29.
    Department of Biochemistry, The James Cook University Hospital, Middlesbrough TS4 3BW, UK.
    Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, resulting in increased fragility and susceptibility to fracture. Osteoporotic fractures are a significant cause of morbidity and mortality. Direct medical costs from such fractures in the UK are currently estimated at over two billion pounds per year, resulting in a substantial healthcare burden that is expected to rise exponentially due to increasing life expectancy. Read More

    Chemical structure, biosynthesis and synthesis of free and glycosylated pyridinolines formed by cross-link of bone and synovium collagen.
    Org Biomol Chem 2013 Sep;11(35):5747-71
    Department of Biomedical Sciences for Health, University of Milan, via F.lli Cervi 93, 20090 Segrate (Milan), Italy.
    This review focuses on the chemical structure, biosynthesis and synthesis of free and glycosylated pyridinolines (Pyds), fluorescent collagen cross-links, with a pyridinium salt structure. Pyds derive from the degradation of bone collagen and have attracted attention for their use as biochemical markers of bone resorption and to assess fracture risk prediction in persons suffering from osteoporosis, bone cancer and other bone or collagen diseases. We consider and critically discuss all reported syntheses of free and glycosylated Pyds evidencing an unrevised chemistry, original and of general utility, analysis of which allows us to also support a previously suggested non-enzymatic formation of Pyds in collagen better rationalizing and justifying the chemical events. Read More

    Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
    Ir J Med Sci 2014 Mar 5;183(1):47-52. Epub 2013 Jun 5.
    Metabolism Laboratory, St. Vincent's University Hospital, Dublin, Ireland,
    Background: Tartrate-resistant acid phosphatase isoform 5b (TRACP5b) is a serum bone resorption marker. Our aim was to investigate its utility in monitoring metabolic bone disease.

    Methods: Serum TRACP5b, C-terminal cross-linking telopeptide of type I collagen, urine N-terminal cross-linking telopeptide of type I collagen and free deoxypyridinoline were measured pre- and post-treatment with a parathyroid hormone analogue [PTH (1-34)] (n = 14) or a bisphosphonate (N-BP) (n = 8). Read More

    Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients.
    Clin Lab 2012 ;58(7-8):845-50
    Department of Orthopaedics, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, P. R. China.
    Background: The goal was to find out the clinical significances of tartrate-resistant acid phosphatase isoform 5b (TRACP 5b), a biomarker of bone resorption, and bone alkaline phosphatase (BAP) and osteocalcin, two markers of bone formation, in evaluating the osteoporotic fracture risk in Chinese patients.

    Methods: Thirty six Chinese osteoporotic fracture patients and 32 Chinese healthy subjects were included in the study. Bone mineral density (BMD) of lumbar spine and total body were determined by dual-energy X-ray absorptiometry in all subjects. Read More

    National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.
    Osteoporos Int 2012 Oct 14;23(10):2425-33. Epub 2012 Jul 14.
    University of California, San Francisco, USA.
    Unlabelled: This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers.

    Introduction: Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. Read More

    Developing novel prognostic biomarkers for multivariate fracture risk prediction algorithms.
    Calcif Tissue Int 2012 Sep 11;91(3):204-14. Epub 2012 Jul 11.
    Cranfield Health, Cranfield University, Cranfield, UK.
    Multivariate prediction algorithms such as FRAX® and QFractureScores provide an opportunity for new prognostic biomarkers to be developed and incorporated, potentially leading to better fracture prediction. As more research is conducted into these novel biomarkers, a number of factors need to be considered for their successful development for inclusion in these algorithms. In this review, we describe two well-known multivariate prediction algorithms for osteoporosis fracture risk applicable to the UK population, FRAX and QFractureScores, and comment on the current prognostic tools available for fracture risk; dual X-ray assessment, quantitative ultrasonography, and genomic/biochemical markers. Read More

    Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation.
    Int J Womens Health 2012 12;4:167-74. Epub 2012 Apr 12.
    Department of Orthopedics and Traumatology, University Hospital Queen Giovanna - ISUL.
    Bisphosphonates are the most widely prescribed treatment for postmenopausal osteoporosis, secondary osteoporosis, and male osteoporosis. Notwithstanding their high effectiveness and favorable safety profile, the adherence to bisphosphonate treatment remains low. Different treatment strategies aim to improve the clinical effectiveness of bisphosphonate therapy. Read More

    Biochemical bone turnover markers and osteoporosis in older men: where are we?
    J Osteoporos 2011 15;2011:704015. Epub 2011 Dec 15.
    INSERM UMR 1033, Université de Lyon, Hôpital Edouard Herriot, Pavillon F, Place d'Arsonval, 69437 Lyon, France.
    In men aged less than 60, the association of serum and urinary levels of biochemical bone turnover markers (BTMs) and bone mineral density (BMD) is weak or not significant. After this age, higher BTM levels are correlated weakly, but significantly, with lower BMD and faster bone loss. Limited data from the cohort studies suggest that BTM measurement does not improve the prediction of fragility fractures in older men in comparison with age, BMD, history of falls and fragility fractures. Read More

    Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.
    CPT Pharmacometrics Syst Pharmacol 2012 Nov 14;1:e14. Epub 2012 Nov 14.
    Pfizer, Pharmacometrics, Global Clinical Pharmacology, Cambridge, Massachusetts, USA.
    A mathematical model component that extends an existing physiologically based multiscale systems pharmacology model (MSPM) of calcium and bone homeostasis was developed, enabling prediction of nonlinear changes in lumbar spine bone mineral density (LSBMD). Data for denosumab, a monoclonal antibody osteoporosis treatment, dosed at several levels and regimens, was used for fitting the BMD component. Bone marker and LSBMD data extracted from the literature described on/off-treatment effects of denosumab over 48 months [Miller, P. Read More

    Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options.
    Womens Health (Lond) 2011 Nov;7(6):689-98
    Department of Bone Biology & Biomarkers, Nordic Bioscience A/S, Herlev, Denmark.
    Monitoring bone turnover of the adult and aging skeleton is essential for optimal treatment of bone metabolic diseases, such as postmenopausal osteoporosis. Diagnosis of osteoporosis is based solely on dual-emission x-ray absorptiometry-based measurements of bone mineral density. However, within the last 20 years, biochemical markers of bone turnover have been implemented to a larger degree, and especially within the field of drug development. Read More

    Fracture risk assessment in patients with chronic kidney disease.
    Osteoporos Int 2012 Apr 8;23(4):1191-8. Epub 2011 Sep 8.
    Department of Medicine, University of Toronto, Toronto, ON, Canada.
    Fractures are common in patients with chronic kidney disease (CKD) and associated with substantially high morbidity and mortality. Bone mass measurements are commonly used to assess fracture risk in the general population, but the utility of these measurements in patients with CKD, and specifically among those on hemodialysis, is unclear. This review will outline the epidemiology and etiology of fractures in patients with CKD with a particular emphasis on men and women on hemodialysis. Read More

    Clinical utility of denosumab for treatment of bone loss in men and women.
    Clin Interv Aging 2011 24;6:119-24. Epub 2011 May 24.
    Endocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USA.
    While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs have side effects, remain in bone for extended periods, and lead to poor adherence to chronic treatment. Denosumab is a humanized monoclonal antibody and antiresorptive agent that works by decreasing the activity of the receptor activator of nuclear factor kappa B ligand. In major trials in postmenopausal women, denosumab increased bone mineral density by dual energy x-ray absorptiometry in the spine, hip, and distal third of the radius and decreased vertebral, nonvertebral, and hip fractures. Read More

    Effect of vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia.
    Endocr Pract 2011 Nov-Dec;17(6):873-9
    Department of Medicine, Division of Endocrinology and Metabolism, Loyola University Medical Center, Maywood, Illinois 60153, USA.
    Objective: To (1) assess the rate of reduction in bone turnover with vitamin D and bisphosphonate therapies and (2) evaluate the clinical utility of bone-specific alkaline phosphatase (BSAP) in monitoring treatment response.

    Methods: We retrospectively reviewed medical records of patients with newly diagnosed osteopenia and osteoporosis from 2002 to 2009 at Loyola University Medical Center. A cohort of postmenopausal women with hip or spine T-scores of less than -1, normal serum creatinine, and no prior vitamin D or bisphosphonate therapy was divided into vitamin D-deficient (n = 29) and vitamin D-sufficient (n = 13) groups. Read More

    Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review.
    Semin Arthritis Rheum 2011 Oct 19;41(2):157-69. Epub 2011 Apr 19.
    Paris Descartes University, Cochin Hospital, Department of Rheumatology B, Paris, France.
    Objectives: Serum bone turnover markers (sBTM) are used in clinical practice for patients undergoing postmenopausal osteoporosis therapy. The aim of this study was to systematically analyze the literature on the ability of sBTM to monitor therapy, focusing on the following 5 objectives: (1) pretreatment values and treatment choice; (2) short-term changes and clinical response; (3) sBTM effect on persistence to therapy; (4) sBTM ability to predict fracture risk after withdrawal of therapy; and (5) the prediction of serious adverse effects.

    Methods: A systematic search on Medline completed manually was performed until November 2010 and was limited to postmenopausal osteoporosis and marketed therapies. Read More

    Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone.
    Ann N Y Acad Sci 2011 Feb 29;1218:80-7. Epub 2010 Sep 29.
    Department of Medicine, Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
    Osteonecrosis of the jaw (ONJ) has been hypothesized to result in part from a relative "oversuppression" of normal physiologic bone remodeling at the jaw brought about by bisphosphonate therapy. Biochemical markers of bone turnover give readily measurable information on integrated systemic bone remodeling activity, as measured by blood and urine assays. The intra- and interassay variability of most currently available assays is less than 10%, although many biological factors can influence levels of bone turnover markers. Read More

    [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    Ginecol Obstet Mex 2010 Jun;78(6):322-8
    Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León.
    Background: Osteoporosis affects 1 in 3 postmenopausal women and is associated with significant morbidity and mortality. The utility of bisphosphonates is often affected by lack of attachment and acceptance of treatment.

    Objective: To analyze the impact of biofeedback in the adherence to once-monthly oral ibandronate treatment. Read More

    The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.
    J Clin Densitom 2010 Apr-Jun;13(2):181-9. Epub 2010 Mar 27.
    Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
    Bone turnover markers may provide a more rapid indication of patient response to osteoporosis treatment than bone mineral density (BMD) measurements. This post hoc analysis of data from the MOBILE (Monthly Oral iBandronate In LadiEs) study assessed the relationship between increases in BMD at 12 mo from baseline after starting ibandronate treatment and changes in bone resorption marker serum C-terminal telopeptide of type I collagen (sCTX) from baseline at 3 and 6 mo. MOBILE enrolled postmenopausal women aged 55-80 yr with mean lumbar spine (LS) BMD T-score of -2. Read More

    Monitoring pharmacological therapy for osteoporosis.
    Rev Endocr Metab Disord 2010 Dec;11(4):261-73
    New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA.
    Osteoporosis is a common disease characterized by low bone strength that increases the risk of fractures. The consequences of fractures include increases in morbidity, mortality, and healthcare costs. Randomized clinical trials have shown that pharmacological therapy can reduce the risk of fractures. Read More

    The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.
    Eur J Cancer 2009 Dec 21;45(18):3205-12. Epub 2009 Oct 21.
    Department of Endocrinology, Reproductive Medicine, and Osteoporosis, Philipps-University of Marburg, Baldingerstrasse, 35034 Marburg, Germany.
    Introduction: The effects of doxorubicin/cyclophosphamide (A/C; 6 cycles) chemotherapy on bone mineral density (BMD), quantitative ultrasonography (QUS) and bone turnover markers in pre-menopausal women with oestrogen receptor-negative breast cancer (BC) were compared with age-matched controls.

    Methods: Among 106 women (BC=53, controls=53), BMD (spine and hip), QUS (calcaneus and phalanges) and bone marker levels were measured at baseline, 6 and 12 months. Correlations between parameters were determined by Spearman's rho. Read More

    Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
    J Bone Miner Res 2009 Apr;24(4):561-74
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA.
    Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide cross-link of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Read More

    Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug.
    Arthritis Res Ther 2009 26;11(1):R12. Epub 2009 Jan 26.
    CombinatoRx, Incorporated, First Street, Cambridge, MA 02142, USA.
    Introduction: Glucocorticoids are a mainstay of anti-inflammatory therapy, but significant adverse effects ultimately limit their utility. Previous efforts to design glucocorticoid structures with an increased therapeutic window have focused on dissociating anti-inflammatory transcriptional repression from adverse effects primarily driven by transcriptional activation. An alternative to this medicinal chemistry approach is a systems biology based strategy that seeks to amplify selectively the anti-inflammatory activity of very low dose glucocorticoid in immune cells without modulating alternative cellular networks that mediate glucocorticoid toxicity. Read More

    Correlation between bone markers and bone mineral density in postmenopausal women with osteoporosis.
    Endocr Pract 2008 Dec;14(9):1102-7
    Department of Endocrinology, Medwin Hospitals, Hyderabad, India.
    Objective: To study the relationship between bone markers and bone mineral density (BMD) in an effort to identify their utility in postmenopausal women with osteoporosis.

    Methods: Eighty-two consecutive postmenopausal women with untreated osteoporosis were included in the study. Forearm, spinal, and femoral BMD by dual-energy x-ray absorptiometry and markers of bone formation (serum osteocalcin and bone-specific alkaline phosphatase) and bone resorption (urinary free deoxypyridinoline) were measured in all patients. Read More

    [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Nefrologia 2008 ;28 Suppl 3:67-78
    H. Universitario de Canarias.
    Unlabelled: With progression of chronic kidney disease (CKD), disorders of mineral metabolism appear. The classic sequence of events begins with a deficit of calcitriol synthesis and retention of phosphorus. As a result of this, serum calcium decreases and parathyroid hormone (PTH) is stimulated, producing in the bone the high turnover (HT) bone disease known as osteitis fibrosa while on the other extreme we find the forms of low turnover (LT) bone disease. Read More

    Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.
    Mol Diagn Ther 2008 ;12(3):157-70
    INSERM Unit 664, Laënnec School of Medicine, Lyon, France.
    Osteoporosis is a systemic disease characterized by low bone mass and microarchitectural deterioration of bone tissue, resulting in an increased risk of fracture. While the level of bone mass can be estimated by measuring bone mineral density (BMD) using dual X-ray absorptiometry (DXA), its measurement does not capture all the risk factors for fracture. Quantitative changes in skeletal turnover can be assessed easily and non-invasively by the measurement of serum and urinary biochemical markers; the most sensitive markers include serum osteocalcin, bone specific alkaline phosphatase, the N-terminal propeptide of type I collagen for bone formation, and the crosslinked C- (CTX) and N- (NTX) telopeptides of type I collagen for bone resorption. Read More

    Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Ann Pharmacother 2008 Jul 27;42(7):1085-9. Epub 2008 May 27.
    Harrison School of Pharmacy, Auburn University, AL, USA.
    Objective: To review studies that investigated the use of once-yearly administered intravenous zoledronic acid for the treatment of postmenopausal osteoporosis.

    Data Sources: Searches of MEDLINE (1966-February 2008) and EMBASE (1974-February 2008) were conducted using the terms zoledronic acid, once-yearly, and postmenopausal osteoporosis. Literature review was limited to human studies. Read More

    [How should the response to osteoporosis treatment be evaluated?].
    Rev Clin Esp 2008 May;208(5):247-50
    Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain.
    Osteoporosis is a disease with high morbidity-mortality that is important because it predisposes to fractures. Thus, treatment of this disease is aimed at preventing them. However, and in spite of the fact that the fracture is the truly important consequence of therapeutic failure, it should not be considered to be an exponent of it given that it may be due to factors not related with lack of response such as intrinsic predisposition of the disease to development of fractures or being prone to falls. Read More

    Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis.
    Crit Rev Clin Lab Sci 2008 ;45(2):221-58
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, WA, Australia.
    Biochemical markers of bone turnover (bone-turnover markers) are released during bone formation or resorption and can be measured in blood and/or urine. The concentration of bone-turnover markers in serum or urine reflect bone remodeling activity and can potentially be used as surrogate markers of the rate of bone formation or bone resorption. While the diagnosis of osteoporosis is based on bone mineral density (BMD), the absolute fracture risk for a particular BMD measurement varies several fold depending on age and is also influenced by other clinical risk factors. Read More

    Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone.
    Eur J Intern Med 2008 Jan 26;19(1):51-6. Epub 2007 Nov 26.
    University Hospital Insular, Department of Internal Medicine, Bone Metabolic Unit, University of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Canary Islands, Spain.
    Background: Daily doses higher than 7.5 mg/daily of prednisone or equivalents confer a great risk of vertebral and hip fractures with a clear dose dependence of fracture risk. Information regarding the utility in assessing trabecular bone mineral density by quantitative computer tomography (QCT) in these patients, either in the Canaries or in Spain, is lacking. Read More

    The use of biochemical markers of bone turnover in osteoporosis.
    P R Health Sci J 2007 Jun;26(2):91-5
    Endocrine Section, University of Puerto Rico, School of Medicine GPO Box 365067, San Juan, Puerto Rico 00936-5067.
    Objective: Present evidence-based recommendations on the use of biochemical markers of bone turnover in the management of osteoporosis.

    Methods: The English literature from 1999 to 2005 was reviewed by using data sources from MEDLINE.

    Results: Measurement of biochemical markers of bone turnover helps us identify a high bone turnover rate. Read More

    Future developments in therapy.
    Ann N Y Acad Sci 2007 Nov 21;1117:258-63. Epub 2007 Jun 21.
    Department of Orthopaedic Surgery, Medical College of Georgia, Institute of Molecular Medicine and Genetics, Augusta, Georgia 30912, USA.
    An exciting new era in bone biology is a result of our greater understanding not only of the mechanisms of action of the medications we currently use for treatment of osteoporosis but also of the molecular pathways involved in normal and abnormal bone formation. In the coming years our increased understanding of these molecular pathways will result in many new medications for osteoporosis therapy. Together with the development of new drugs it will be necessary to develop better ways of assessing bone quality. Read More

    Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation.
    Clin Chem Lab Med 2007 ;45(8):1014-8
    Biochemistry Laboratory, General Hospital Jesenice, Jesenice, Slovenia.
    Background: Recently published data identified bone-specific alkaline phosphatase (BALP) as a good marker of bone formation in different bone diseases and osteoporosis. Two methods are available for BALP determination: one measures enzyme activity, the other its mass concentration. We compared results for BALP activity and its mass concentration in a group of 88 healthy pre- and postmenopausal women to identify which is a more useful marker for detecting early menopausal bone remodelling changes. Read More

    Bone formation markers in adults with mild osteogenesis imperfecta.
    Clin Chem 2007 Jun 13;53(6):1109-14. Epub 2007 Apr 13.
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
    Background: Plasma concentrations of procollagen peptides are decreased in osteogenesis imperfecta (OI), whereas other bone formation markers may be increased. We examined the utility of combining these markers in the diagnosis of OI in adults.

    Methods: We measured plasma concentrations of procollagen-1 N-peptide (P1NP), osteocalcin, and bone alkaline phosphatase in 24 patients with nondeforming OI, 25 patients with low bone mass due to other causes, and 38 age- and sex-matched controls. Read More

    1 OF 2